Theravance Gets To Market With Vibativ, But HAP Indication Could Be Pushed To 2010
This article was originally published in The Pink Sheet Daily
Executive Summary
Theravance expects an FDA advisory committee review for Vibativ in hospital acquired pneumonia; product partnered with Astellas is approved for complicated skin infections.